The dynamics of the pandemic, including multi-country shutdowns, put an excessive amount of pressure on healthcare supply chains worldwide. There are clear signs that COVID-19 will be here for some time, driving healthcare companies to address supply chain vulnerabilities. Pharmaceutical companies relied heavily on an unprecedented level of cooperation from raw material suppliers, government agencies, and contract development and manufacturing organizations. Medical device companies took a hard look at inventory management, business continuity planning, and risk management functions. The unquestionable impact of these shifts results from three merging drivers of change—coordinated management, flexible manufacturing strategies, and seamless mobility. All are critical elements of agility in revamping supply chains.
Key Takeaways:
- Learn how to optimize supply chain networks.
- Gain insight into new strategies for the medical device and pharmaceutical industries.
- Identify growth opportunities in a post-COVID-19 environment.
